What is the 13F Pro Quality Score for ARQT?

13F Pro ranks Arcutis Biotherapeutics, Inc. (ARQT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ARQT's current score at https://13fpro.ai/company/ARQT (free sign-up required for the full ranking).

Where does 13F Pro source ARQT data?

All Arcutis Biotherapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Arcutis Biotherapeutics, Inc. files with the SEC under CIK 1787306. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ARQT in?

Arcutis Biotherapeutics, Inc. (ARQT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ARQT research updated on 13F Pro?

ARQT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Arcutis Biotherapeutics, Inc.(ARQT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1787306 ARQT stock profile & AI dashboard →

13F Pro Quality Score

62.9/100

Rank #675 of 2,962 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

96.6/100

Profitability

66.0/100

Balance Sheet

76.5/100

Earnings Quality

71.2/100

Free Cash Flow

51.8/100

Institutional Flow

21.1/100

Revenue Scale

36.1/100

Dilution Risk

15.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ARQT Scores 63/100

exact factor attribution · 2026-09-11

ARQT's composite is driven by revenue growth and capital efficiency, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.3 pts

97th pct

Capital efficiency

+2.6 pts

77th pct

Profitability

+2.4 pts

66th pct

Earnings quality

+2.1 pts

71th pct

Earnings growth

+1.4 pts

78th pct

Free cash flow

+0.3 pts

52th pct

Institutional flow

-1.4 pts

21th pct

Shareholder dilution

-1.7 pts

16th pct

Scale

-2.1 pts

36th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ARQT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Arcutis Biotherapeutics, Inc. (ARQT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARQT at 62.9/100 on a 32-signal composite quality model, placing it at rank #675 of 2,962 stocks — the top 25% of the AI-ranked universe. ARQT scores in the top quartile across revenue growth (96.6), balance sheet strength (76.5). Areas of concern include institutional flow (21.1) and revenue scale (36.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Arcutis Biotherapeutics, Inc. reports quarterly revenue of $129.9M, net income of $15.0M, free cash flow of $12.5M. Top institutional holders of ARQT by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, BlackRock, Frazier Life Sciences Management, L.P., based on the most recent SEC filings. ARQT trades on the Nasdaq exchange and files with the SEC under CIK 1787306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARQT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcutis Biotherapeutics, Inc. directly from SEC EDGAR. Arcutis Biotherapeutics, Inc.'s 13F Pro composite quality score has ranged between 32 and 63 since 2025, currently 62.9 — an improving long-term trajectory across 51 quarterly and live scoring snapshots.

✦

Fun facts about Arcutis Biotherapeutics, Inc.

Quirks, history, and lore behind ARQT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, still on the path to profitability — a classic commercial-stage biotech burning cash to build market share.
3
The History
Founded around 2016 and went public in 2021, it was built from the ground up with a singular focus: diseases that live on the surface of your body — namely, the skin.
4
The Secret
Its entire pipeline targets dermatological conditions — think plaque psoriasis, seborrheic dermatitis, and eczema — using novel topical formulations designed to work better with fewer side effects.
5
The Lore
Its flagship product, a roflumilast cream, was the first PDE4 inhibitor approved as a topical treatment for plaque psoriasis — a genuine first-in-class dermatology win.
6
The Giveaway
A pure-play derm biotech whose name blends "arcuate" (think skin curves) with "cutis" — Latin for skin — and trades under the ticker ARQT.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$129.9M

Net Income

Q2 2026

$15.0M

Free Cash Flow

Q2 2026

$12.5M

ROIC

Q2 2026

19.5%

D/E Ratio

Q2 2026

0.53

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+91.3% YoY

$376.1MFY 2025

FY22 $3.7MFY23 $59.6MFY24 $196.5MFY25 $376.1M

Net Income

+88.5% YoY

$-16.1MFY 2025

FY22 $-311.5MFY23 $-262.1MFY24 $-140.0MFY25 $-16.1M

Operating Income

+90.5% YoY

$-12.2MFY 2025

FY22 $-301.6MFY23 $-241.1MFY24 $-128.4MFY25 $-12.2M

EPS (Diluted)

+88.8% YoY

$-0.13FY 2025

FY22 $-5.66FY23 $-3.78FY24 $-1.16FY25 $-0.13

Total Assets

+24.1% YoY

$433.0MFY 2025

FY22 $449.3MFY23 $341.4MFY24 $348.9MFY25 $433.0M

Total Debt

+2.6% YoY

$110.0MFY 2025

FY22 $197.8MFY23 $201.8MFY24 $107.2MFY25 $110.0M

Op. Cash Flow

+95.0% YoY

$-5.6MFY 2025

FY22 $-257.7MFY23 $-247.1MFY24 $-112.2MFY25 $-5.6M

Free Cash Flow

+94.4% YoY

$-6.3MFY 2025

FY22 $-258.0MFY23 $-247.5MFY24 $-112.3MFY25 $-6.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$376.1M +91.3%	$196.5M +229.7%	$59.6M +1517.1%	$3.7M	$0.00	$0.00
Net Income	$-16.1M +88.5%	$-140.0M +46.6%	$-262.1M +15.8%	$-311.5M -50.9%	$-206.4M -52.1%	$-135.7M
Operating Income	$-12.2M +90.5%	$-128.4M +46.7%	$-241.1M +20.1%	$-301.6M -46.0%	$-206.5M -51.1%	$-136.6M
EPS (Diluted)	$-0.13 +88.8%	$-1.16 +69.3%	$-3.78 +33.2%	$-5.66 -35.4%	$-4.18 -10.0%	$-3.80
Total Assets	$433.0M +24.1%	$348.9M +2.2%	$341.4M -24.0%	$449.3M +10.1%	$408.2M +36.8%	$298.3M
Total Debt	$110.0M +2.6%	$107.2M -46.9%	$201.8M +2.0%	$197.8M +173.4%	$72.3M	$0.00
Operating Cash Flow	$-5.6M +95.0%	$-112.2M +54.6%	$-247.1M +4.1%	$-257.7M -47.6%	$-174.6M -54.5%	$-113.0M
Free Cash Flow	$-6.3M +94.4%	$-112.3M +54.6%	$-247.5M +4.1%	$-258.0M -46.9%	$-175.6M -54.9%	$-113.4M

Get alerted when ARQT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Arcutis Biotherapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ARQT

SUVRETTA CAPITAL MANAGEMENT, LLC
$326.1M12,437,000 sh
BlackRock, Inc.
$276.5M10,545,466 sh
Frazier Life Sciences Management, L.P.
$258.9M9,874,511 sh
Rubric Capital Management LP
$216.9M8,271,577 sh
Polar Capital Holdings Plc
$173.2M6,606,945 sh
STATE STREET CORP
$152.7M5,822,840 sh
VANGUARD CAPITAL MANAGEMENT LLC
$130.8M4,988,756 sh
MORGAN STANLEY
$116.7M4,451,014 sh
JENNISON ASSOCIATES LLC
$110.6M4,219,058 sh
D. E. Shaw & Co., Inc.
$103.6M3,949,609 sh

Fund	Value	Shares
SUVRETTA CAPITAL MANAGEMENT, LLC	$326.1M	12,437,000
BlackRock, Inc.	$276.5M	10,545,466
Frazier Life Sciences Management, L.P.	$258.9M	9,874,511
Rubric Capital Management LP	$216.9M	8,271,577
Polar Capital Holdings Plc	$173.2M	6,606,945
STATE STREET CORP	$152.7M	5,822,840
VANGUARD CAPITAL MANAGEMENT LLC	$130.8M	4,988,756
MORGAN STANLEY	$116.7M	4,451,014
JENNISON ASSOCIATES LLC	$110.6M	4,219,058
D. E. Shaw & Co., Inc.	$103.6M	3,949,609

Companies Similar to ARQT

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

TARS

Tarsus Pharmaceuticals, Inc.

AI score

Similar quality profile · 22 shared holders

JENNISON ASSOCIATES LLC Frazier Life Sciences Management, L.P.DRIEHAUS CAPITAL MANAGEMENT LLC

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 14 shared holders

abrdn plc OBERWEIS ASSET MANAGEMENT INC/Rubric Capital Management LP

MGTX

MeiraGTx Holdings plc

AI score

Similar quality profile · 12 shared holders

Rubric Capital Management LP PFM Health Sciences, LP Privium Fund Management B.V.

ETON

Eton Pharmaceuticals, Inc.

AI score

Similar quality profile · 9 shared holders

OBERWEIS ASSET MANAGEMENT INC/ESSEX INVESTMENT MANAGEMENT CO LLC PDT Partners, LLC

KNSA

Kiniksa Pharmaceuticals International, plc

AI score

Similar quality profile · 22 shared holders

Rubric Capital Management LP ORBIMED ADVISORS LLC OBERWEIS ASSET MANAGEMENT INC/

CAI

Caris Life Sciences, Inc.

AI score

Similar quality profile · 7 shared holders

ORBIMED ADVISORS LLC China Universal Asset Management Co., Ltd.Entropy Technologies, LP

ALNY

ALNYLAM PHARMACEUTICALS, INC.

AI score

Similar quality profile · 12 shared holders

Polar Capital Holdings Plc GILDER GAGNON HOWE & CO LLC abrdn plc

LFST

LifeStance Health Group, Inc.

AI score

Similar quality profile · 8 shared holders

JENNISON ASSOCIATES LLC ORBIMED ADVISORS LLC MYDA Advisors LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ARQT on your watchlist

Track score changes the day Arcutis Biotherapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ARQT a good stock to buy?

13F Pro's AI-powered analysis of Arcutis Biotherapeutics, Inc. (ARQT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARQT are available on the ARQT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ARQT is classified as a mid company.

Which hedge funds own ARQT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARQT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Arcutis Biotherapeutics, Inc.'s investment landscape.